Brokerages Set Kezar Life Sciences, Inc. (NASDAQ:KZR) Target Price at $9.00

Kezar Life Sciences, Inc. (NASDAQ:KZR) has earned an average rating of “Reduce” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $6.00.

A number of equities research analysts have recently commented on KZR shares. TD Cowen cut shares of Kezar Life Sciences from a “strong-buy” rating to a “strong sell” rating in a report on Friday. Wall Street Zen raised shares of Kezar Life Sciences to a “sell” rating in a report on Saturday, September 13th. HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Wednesday, July 16th. Wells Fargo & Company set a $5.00 target price on shares of Kezar Life Sciences and gave the company an “equal weight” rating in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kezar Life Sciences in a report on Wednesday, October 8th.

Kezar Life Sciences Price Performance

Shares of KZR opened at $6.36 on Friday. Kezar Life Sciences has a 1-year low of $3.53 and a 1-year high of $8.45. The stock has a market cap of $46.56 million, a PE ratio of -0.66 and a beta of 0.62. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.29 and a quick ratio of 7.29. The firm has a fifty day moving average price of $4.00 and a 200 day moving average price of $4.19.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.28. As a group, sell-side analysts anticipate that Kezar Life Sciences will post -4.39 EPS for the current year.

Institutional Investors Weigh In On Kezar Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Woodline Partners LP purchased a new position in Kezar Life Sciences during the first quarter worth about $125,000. Stonepine Capital Management LLC raised its holdings in Kezar Life Sciences by 69.9% during the second quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock worth $778,000 after purchasing an additional 69,859 shares in the last quarter. Finally, BML Capital Management LLC raised its holdings in Kezar Life Sciences by 738.6% during the first quarter. BML Capital Management LLC now owns 408,138 shares of the company’s stock worth $1,992,000 after purchasing an additional 359,470 shares in the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.